TNG462 / DARAXON portfolio
Vopimetostat API
TNG462 active pharmaceutical ingredient for PRMT5 / MTAP-deletion research and development. U.S. FDA DMF 44318.
Product overview
Active pharmaceutical ingredient
Vopimetostat, also known as TNG462, is an investigational MTA-cooperative PRMT5 inhibitor being studied in MTAP-deleted cancers. Daraxon offers vopimetostat API with project-specific technical and regulatory documentation requirements agreed before supply.
Tango Therapeutics · PRMT5 programs↗- Product
- Vopimetostat API
- Development code
- TNG462
- Material format
- Active pharmaceutical ingredient
- Research context
- PRMT5 / MTAP-deleted cancers
- U.S. FDA DMF
- 44318 · Type II
- Submission date
- 2026-06-11
- Status in the 2026 Q2 list
- A — Active
- FDA-listed holder
- SHANGHAI DA'AN XIN BIOMEDICAL CO LTD
Traceable filing record
FDA DMF 44318
Checked against the FDA 2026 Q2 DMF list. This is the only record under this product name in that quarterly list. A DMF filing is not FDA drug approval.
Technical documentation
Define the package for your program.
- Batch Certificate of Analysis and agreed product specification
- Identity and chromatographic records within the agreed documentation package
- DMF reference and Letter of Authorization requirements
Product inquiry
Talk to the Daraxon team.
Include intended use, quantity, destination and documentation requirements.